Bkemv is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria and for those with atypical hemolytic uremic syndrome, according to a May 28 news release from the FDA.
Bkemv is the 53rd approved biosimilar in the U.S.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
